Nivolumab Bests Placebo in MIBC

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with or without prior neoadjuvant chemotherapy.
Medscape Medical News

source https://www.medscape.com/viewarticle/bladder-cancer-survival-better-nivolumab-than-placebo-new-2025a10004ir?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?